Market Overview

Mylan Announces Settlement Related to Comtan

Related MYL
Mylan Launches First Generic Version Of Orapred ODT
Mylan Receives Tentative FDA Approval For Pediatric Formulations Of Abacavir/Lamivudine Through Innovative Collaboration With ViiV Healthcare And Clinton Health Access Initiative
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Orion Corporation that will resolve patent litigation related to Entacapone Tablets, 200 mg. Entacapone Tablets are the generic version of Orion's Comtan^®, indicated as an adjunct to levodopa/carbidopa therapy to treat patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".

Under the terms of the settlement agreement, Mylan may launch a generic version of Comtan, 200 mg, on April 1, 2013, at the earliest. Pursuant to the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Entacapone Tablets, 200 mg, had U.S. sales of approximately $104.9 million for the 12 months ending Sept. 30, 2012, according to IMS Health.

Posted-In: News Legal

 

Related Articles (MYL)

Around the Web, We're Loving...

Get Benzinga's Newsletters